NYSE:ENFN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	283	N/A	N/A	N/A	3
12/31/2025	243	25	45	58	8
12/31/2024	206	12	24	35	8
3/31/2024	182	2	16	26	N/A
12/31/2023	175	6	16	26	N/A
9/30/2023	169	6	17	27	N/A
6/30/2023	163	6	15	22	N/A
3/31/2023	157	3	12	19	N/A
12/31/2022	150	-9	6	14	N/A
9/30/2022	142	-208	-7	1	N/A
6/30/2022	132	-207	-18	-9	N/A
3/31/2022	121	-200	-14	-5	N/A
12/31/2021	112	-188	-8	0	N/A
9/30/2021	103	-1	-13	-5	N/A
6/30/2021	93	2	-3	3	N/A
3/31/2021	85	3	-7	-1	N/A
12/31/2020	80	4	-3	2	N/A
12/31/2019	59	13	8	12	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ENFNの予測収益成長率 (年間99% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: ENFNの収益 ( 99% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: ENFNの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: ENFNの収益 ( 16% ) US市場 ( 8.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: ENFNの収益 ( 16% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ENFNの自己資本利益率は、3年後には高くなると予測されています ( 28.5 %)

Enfusion 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 38%

Consensus EPS estimates fall by 20%, revenue upgraded

Consensus EPS estimates fall by 32%

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased by 7.0% to US$10.43

Price target decreased by 7.1% to US$11.21

Recent updates

Enfusion: Expectations Of Faster Growth And Higher Margins Justify A Buy Rating

New minor risk - Shareholder dilution

Chief People Officer recently sold US$325k worth of stock

Chief People Officer notifies of intention to sell stock

Consensus EPS estimates fall by 38%

New minor risk - Profit margin trend

First quarter 2024 earnings: EPS misses analyst expectations

Enfusion, Inc., Annual General Meeting, Jun 13, 2024

Enfusion, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus EPS estimates fall by 20%, revenue upgraded

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Is Now An Opportune Moment To Examine Enfusion, Inc. (NYSE:ENFN)?

New minor risk - Shareholder dilution

Now 20% undervalued after recent price drop

Capital Allocation Trends At Enfusion (NYSE:ENFN) Aren't Ideal

Enfusion, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Now 22% undervalued

New minor risk - Shareholder dilution

Enfusion, Inc. Elevates Valeria Gutowski to Chief Accounting Officer

Enfusion: Product Is Sticky And Industry Is Huge

Calculating The Fair Value Of Enfusion, Inc. (NYSE:ENFN)

CEO & Director recently sold US$1.0m worth of stock

New minor risk - Shareholder dilution

CEO & Director recently sold US$1.5m worth of stock

CEO & Director notifies of intention to sell stock

Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%

Managing Partner recently sold US$9.9m worth of stock

Enfusion, Inc. Appoints Neal Pawar as Chief Operating Officer, Effective November 27, 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 32%

Enfusion: Still Bullish Considering Q3 EBITDA Beat

Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching

Enfusion, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Shareholder dilution

Enfusion Faces Cross-Currents In Investment Management Software Market

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased by 7.0% to US$10.43

Enfusion, Inc. Appoints Andi Woolass as Head of Partnerships and Alliances for EMEA

Enfusion Reportedly Draws Takeover Interest from Private Equity, Irenic Capital

Enfusion: Multiple Catalysts

Now 21% undervalued after recent price drop

Price target decreased by 7.1% to US$11.21

Chief Technology Officer recently sold US$396k worth of stock

Chief Technology Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

Chief Technology Officer recently sold US$126k worth of stock

Chief Technology Officer notifies of intention to sell stock

First quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

Insider recently sold US$20m worth of stock

Full year 2022 earnings released: US$0.15 loss per share (vs US$2.26 loss in FY 2021)

Enfusion, Inc.'s (NYSE:ENFN) Intrinsic Value Is Potentially 32% Above Its Share Price

Enfusion, Inc. to Report Q4, 2022 Results on Mar 07, 2023

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Enfusion, Inc. Names Michael Spellacy as Board Chair and Non-Executive Director

Price target decreased to US$12.80

Enfusion, Inc. Names Oleg Movchan as Chief Executive Officer

Enfusion, Inc. Appoints Brad Herring as Chief Financial Officer

Enfusion brings on Shift4 Payments' Brad Herring as CFO

Enfusion, Inc. Welcomes New Addition to Board of Directors, Effective January 1, 2023

Enfusion, Inc. Announces Resignation of Stephen Dorton as Chief Financial Officer, Effective January 6, 2023

Insider recently sold US$12m worth of stock

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Enfusion, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Enfusion Expands Offerings As Revenue Growth Decelerates

Enfusion, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Enfusion, Inc. (NYSE:ENFN) Shares Could Be 49% Below Their Intrinsic Value Estimate